Telomere maintenance and disease

Lancet

Volumn 362, Issue 9388, 2003, Pages 983-988

  Wong, Judy M Y ^a   Collins, Kathleen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW TRANSPLANTATION; CELL CULTURE; CELL PROLIFERATION; CELL TRANSFORMATION; DNA DAMAGE; DNA SYNTHESIS; ENZYME ACTIVATION; GENE THERAPY; HEMATOPOIETIC CELL; HUMAN; PREMATURITY; PRIORITY JOURNAL; REVIEW; SOMATIC CELL; TELOMERE; TUMOR GROWTH;

EID: 0141763835     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14369-3     Document Type: Review

References (74)

1. McEachern M.J., Krauskopf A., Blackburn E.H. Telomeres and their control. Annu Rev Genet. 34:2000;331-358.
2. de Lange T. Protection of mammalian telomeres. Oncogene. 21:2002;532-540.
3. Price C.M. Telomeres and telomerase: broad effects on cell growth. Curr Opin Genet Dev. 9:1999;218-224.
4. Harley C.B. Telomerase is not an oncogene. Oncogene. 21:2002;494-502.
5. Goytisolo F.A., Blasco M.A. Many ways to telomere dysfunction: in vivo studies using mouse models. Oncogene. 21:2002;584-591.
6. Harrington L., Robinson M.O. Telomere dysfunction: multiple paths to the same end. Oncogene. 21:2002;592-597.
7. Hackett J.A., Greider C.W. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene. 21:2002;619-626.
8. Blackburn E.H. The end of the (DNA) line. Nat Struct Biol. 7:2000;847-850.
9. Henson J.D., Neumann A.A., Yeager T.R., Reddel R.R. Alternative lengthening of telomeres in mammalian cells. Oncogene. 21:2002;598-610.
10. Feng J., Funk W.D., Wang S., et al. The RNA component of human telomerase. Science. 269:1995;1236-1241.
11. Mitchell J.R., Cheng J., Collins K. A box H/ACA small nucleolar RNA-like domain at the human telomerase RNA 3′ end. Mol Cell Biol. 19:1999;567-576.
12. Mitchell J.R., Wood E., Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 402:1999;551-555.
13. Mitchell J.R., Collins K. Human telomerase activation requires two independent interactions between telomerase RNA and telomerase reverse transcriptase in vivo and in vitro. Mol Cell. 6:2000;361-371.
14. Pogacic V., Dragon F., Filipowicz W. Human H/ACA small nucleolar RNPs and telomerase share evolutionarily conserved proteins NHP2 and NOP10. Mol Cell Biol. 20:2000;9028-9040.
15. Dragon F., Pogacic V., Filipowicz W. In vitro assembly of human H/ACA small nucleolar RNPs reveals unique features of U17 and telomerase RNAs. Mol Cell Biol. 20:2000;3037-3048.
16. Nakamura T.M., Cech T.R. Reversing time: origin of telomerase. Cell. 92:1998;587-590.
17. Ford L.P., Wright W.E., Shay J.W. A model for heterogeneous nuclear ribonucleoproteins in telomere and telomerase regulation. Oncogene. 21:2002;580-583.
18. Wright W.E., Piatyszek M.A., Rainey W.E., Byrd W., Shay J.W. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet. 18:1996;173-179.
19. Prowse K.R., Greider C.W. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci USA. 92:1995;4818-4822.
20. Bodnar A.G., Ouellette M., Frolkis M., et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 279:1998;349-352.
21. Ulaner G.A., Hu J., Vu T.H., Giudice L.C., Hoffman A.R. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res. 58:1998;4168-4172.
22. Collins K., Mitchell J.R. Telomerase in the human organism. Oncogene. 21:2002;564-579.
23. Artandi S.E., DePinho R.A. A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr Opin Genet Dev. 10:2000;39-46.
24. Aisner D.L., Wright W.E., Shay J.W. Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev. 12:2002;80-85.
25. Wong J.M., Kusdra L., Collins K. Subnuclear shuttling of human telomerase induced by transformation and DNA damage. Nat Cell Biol. 4:2002;731-736.
26. Smogorzewska A., van Steensel B., Bianchi A., et al. Control of human telomere length by TRF1 and TRF2. Mol Cell Biol. 20:2000;1659-1668.
27. Chiu C.-P., Dragowska W., Kim K.W. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells. 14:1996;239-248.
28. Weng N.-P., Hathcock K.S., Hodes R.J. Regulation of telomere length and telomerase in T and B cells: a mechanism for maintaining replicative potential. Immunity. 9:1998;151-157.
29. Weng N.-P. Regulation of telomerase expression in human lymphocytes. Springer Semin Immunopathol. 24:2002;23-33.
30. Rufer N., Brümmendorf T.H., Kolvraa S., et al. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med. 190:1999;157-167.
31. Son N.H., Murray S., Yanovski J., Hodes R.J., Weng N.-P. Lineage-specific telomere shortening and unaltered capacity for telomerase expression in human T and B lymphocytes with age. J Immunol. 165:2000;1191-1196.
32. Weng N.-P., Granger L., Hodes R.J. Telomere lengthening and telomerase activation during human B cell differentiation. Proc Natl Acad Sci USA. 94:1997;10827-10832.
33. Weng N.-P., Levine B.L., June C.H., Hodes R.J. Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc Natl Acad Sci USA. 92:1995;11091-11094.
34. Bodnar A.G., Kim N.W., Effros R.B., Chiu C.-P. Mechanism of telomerase induction during T cell activation. Exp Cell Res. 228:1996;58-64.
35. Blasco M.A., Lee H., Hande M.P., et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 91:1997;25-34.
36. Blasco M.A. Immunosenescence phenotypes in the telomerase knockout mouse. Springer Semin Immunopathol. 24:2002;75-85.
37. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol. 110:2000;768-779.
38. Heiss N.S., Knight S.W., Vulliamy T.J., et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet. 19:1998;32-38.
39. Kiss T. Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs. EMBO J. 20:2001;3617-3622.
40. Knight S.W., Heiss N.S., Vulliamy T.J., et al. X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. Am J Hum Genet. 65:1999;50-58.
41. He J., Navarrete S., Jasinski M., et al. Targeted disruption of Dkc1, the gene mutated in X-linked dyskeratosis congenita, causes embryonic lethality in mice. Oncogene. 21:2002;7740-7744.
42. Montanaro L., Chilla A., Trere D., et al. Increased mortality rate and not impaired ribosomal biogenesis is responsible for proliferative defect in dyskeratosis congenita cell lines. J Invest Dermatol. 118:2002;193-198.
43. Vulliamy T., Marrone A., Goldman F., et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature. 413:2001;432-435.
44. Maser R.S., DePinho R.A. Connecting chromosomes, crisis and cancer. Science. 297:2002;565-569.
45. Tlsty T.D., Romanov S.R., Kozakiewicz B.K., Holst C.R., Haupt L.M., Crawford Y.G. Loss of chromosomal integrity in human mammary epithelial cells subsequent to escape from senescence. J Mammary Gland Biol Neoplasia. 6:2001;235-243.
46. Knight S.W., Heiss N.S., Vulliamy T.J., et al. Unexplained aplastic anaemia, immunodeficiency, and cerebellar hypoplasia (Hoyeraal-Hreidarsson syndrome) due to mutations in the dyskeratosis congenita gene, DKC1. Br J Haematol. 107:1999;335-339.
47. Yaghmai R., Kimyai-Asadi A., Rostamiani K., et al. Overlap of dyskeratosis congenita with the Hoyeraal-Hreidarsson syndrome. J Pediatrics. 136:2000;390-393.
48. Cossu F., Vulliamy T.J., Marrone A., Badiali M., Cao A., Dokal I. A novel DKC1 mutation, severe combined immunodeficiency (T+B-NK- SCID) and bone marrow transplantation in an infant with Hoyeraal-Hreidarsson syndrome. Br J Haematol. 119:2002;765-768.
49. Vulliamy T.J., Marrone A., Dokal I., Mason P.J. Association between aplastic anaemia and mutations in telomerase RNA. Lancet. 359:2002;2168-2170.
50. Ball S.E., Gibson F.M., Rizzo S., Tooze J.A., Marsh J.C., Gordon-Smith E.C. Progressive telomere shortening in aplastic anemia. Blood. 91:1998;3582-3592.
51. Brummendorf T.H., Maciejewski J.P., Mak J., Young N.S., Lansdorp P.M. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood. 97:2001;895-900.
52. Lee J., Kook H., Chung I., et al. Telomere length changes in patients with aplastic anaemia. Br J Haematol. 112:2001;1025-1030.
53. Effros R.B. Telomeres and HIV disease. Microbes Infect. 2:2000;69-76.
54. Kitada T., Seki S., Kawakita N., Kuroki T., Monna T. Telomere shortening in chronic liver diseases. Biochem Biophys Res Commun. 211:1995;33-39.
55. Aikata H., Takaishi H., Kawakami Y., et al. Telomere reduction in human liver tissues with age and chronic inflammation. Exp Cell Res. 256:2000;578-582.
56. Rudolph K.L., Chang S., Millard M., Schreiber-Agus N., DePinho R.A. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science. 287:2000;1253-1258.
57. Notaro R., Cimmino A., Tabarini D., Rotoli B., Luzzatto L. In vivo telomere dynamics of human hematopoietic stem cells. Proc Natl Acad Sci USA. 94:1997;13782-13785.
58. Wynn R.F., Cross M.A., Hatton C., et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet. 351:1998;178-181.
59. Akiyama M., Hoshi Y., Sakurai S., Yamada H., Yamada O., Mizoguchi H. Changes of telomere length in children after hematopoietic stem cell transplantation. Bone Marrow Transplant. 21:1998;167-171.
60. Lee J.J., Kook H., Chung I.J., et al. Telomere length changes in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 24:1999;411-415.
61. Akiyama M., Asai O., Kuraishi Y., et al. Shortening of telomeres in recipients of both autologous and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 25:2000;441-447.
62. Vessey C.J., Norbury C.J., Hickson I.D. Genetic disorders associated with cancer predisposition and genomic instability. Prog Nucl Acids Res Mol Biol. 63:2000;189-221.
63. Metcalfe J.A., Parkhill J., Campbell L., et al. Accelerated telomere shortening in ataxia telangiectasia. Nat Genet. 13:1996;350-353.
64. Wood L.D., Halvorsen T.L., Dhar S., et al. Characterization of ataxia telangiectasia fibroblasts with extended life-span through telomerase expression. Oncogene. 20:2001;278-288.
65. Ranganathan V., Heine W.F., Ciccone D.N., et al. Rescue of a telomere length defect of Nijmegen breakage syndrome cells requires NBS and telomerase catalytic subunit. Curr Biol. 11:2001;962-966.
66. Leteurtre F., Li X., Guardiola P., et al. Accelerated telomere shortening and telomerase activation in Fanconi's anaemia. Br J Haematol. 105:1999;883-893.
67. Howlett N.G., Taniguchi T., Olson S., et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 297:2002;606-609.
68. Bogliolo M., Cabre O., Callen E., et al. The Fanconi anaemia genome stability and tumour suppressor network. Mutagenesis. 17:2002;529-538.
69. Callen E., Samper E., Ramirez J.L., et al. Breaks at telomeres and TRF2-independent end fusions in Fanconi anemia. Hum Mol Genet. 11:2002;439-444.
70. Hande M.P., Balajee A.S., Tchirkov A., Wynshaw-Boris A., Lansdorp P.M. Extra-chromosomal telomeric DNA in cells from Atm(-/-) mice and patients with ataxia-telangiectasia. Hum Mol Genet. 10:2001;519-528.
71. Sprung C.N., Bryan T.M., Reddel R.R., Murnane J.P. Normal telomere maintenance in immortal ataxia telangiectasia cell lines. Mutat Res. 379:1997;177-184.
72. Hooijberg E., Ruizendaal J.J., Snijders P.J., Kueter E.W., Walboomers J.M., Spits H. Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase. J Immunol. 165:2000;4239-4245.
73. Rufer N., Migliaccio M., Antonchuk J., Humphries R.K., Roosnek E., Lansdorp P.M. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood. 98:2001;597-603.
74. Blasco M.A. Telomerase beyond telomeres. Nat Rev Cancer. 2:2002;1-6.